Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Observation of Treatment Patterns With Lucentis in Approved Indications (NCT02194803) | Novartis Pharmaceuticals | 2011-12-08 |
Track Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV automatically
Every clearance here is in the API, with alerts when new ones post.